Last reviewed · How we verify
DIPHENCYPRONE
At a glance
| Generic name | DIPHENCYPRONE |
|---|---|
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases (PHASE1)
- DPCP for the Treatment of Alopecia Areata (PHASE3)
- Trem-1 and Ultraviolet Radiation-induced Immune Suppression (EARLY_PHASE1)
- DPCP to Treat Cutaneous Neurofibromas Associated With NF1 (PHASE1)
- Diphenylcyclopropenone (DPCP) as a Depigmenting Therapy in Extensive Vitiligo (PHASE4)
- Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers (NA)
- Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) (PHASE1)
- Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DIPHENCYPRONE CI brief — competitive landscape report
- DIPHENCYPRONE updates RSS · CI watch RSS